Our CEO and co-founder, Prof. Rob Collin, will be taking the stage at the Oligonucleotide Therapeutics Society (OTS) Meeting in Budapest on October 20th to talk about “Splicing modulation therapy for inherited retinal diseases.”
Although Rob will be presenting in his capacity as Professor at Radboud University Medical Center, he will also touch upon some of the work we are doing at Astherna to bring ASO-based therapies for rare inherited retinal diseases one step closer to patients.
If you will be at OTS this year, we hope you will join his session or just stop by to say hello 👋
Related Posts
